$CRDF
Cardiff Oncology, Inc.

2020 Q2 Form 10-Q Financial Statement

#000162828020012428 Filed on August 11, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $43.00K $38.35K
YoY Change 12.13% -65.7%
Cost Of Revenue $0.00
YoY Change -100.0%
Gross Profit $38.35K
YoY Change -141.4%
Gross Profit Margin 100.0%
Selling, General & Admin $1.669M $1.428M
YoY Change 16.88% -33.61%
% of Gross Profit 3723.71%
Research & Development $2.476M $2.830M
YoY Change -12.52% 44.94%
% of Gross Profit 7380.67%
Depreciation & Amortization $110.0K $40.00K
YoY Change 175.0% -82.61%
% of Gross Profit 104.31%
Operating Expenses $4.145M $4.258M
YoY Change -2.66% -6.44%
Operating Profit -$4.102M -$4.220M
YoY Change -2.8% -4.95%
Interest Expense -$30.00K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $6.000K $1.106K
YoY Change 442.5% -101.54%
Pretax Income -$4.120M -$4.130M
YoY Change -0.24% 10.13%
Income Tax
% Of Pretax Income
Net Earnings -$4.124M -$4.125M
YoY Change -0.03% 10.1%
Net Earnings / Revenue -9590.7% -10757.54%
Basic Earnings Per Share -$0.51 -$0.79
Diluted Earnings Per Share -$0.51 -$0.79
COMMON SHARES
Basic Shares Outstanding 14.49M shares 5.242M shares
Diluted Shares Outstanding 14.49M shares 5.242M shares

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.80M $10.80M
YoY Change 157.41% -41.62%
Cash & Equivalents $27.80M $10.79M
Short-Term Investments
Other Short-Term Assets $1.000M $900.0K
YoY Change 11.11% -10.0%
Inventory
Prepaid Expenses $955.0K $906.5K
Receivables $109.3K $122.3K
Other Receivables $0.00 $0.00
Total Short-Term Assets $28.82M $11.82M
YoY Change 143.82% -39.83%
LONG-TERM ASSETS
Property, Plant & Equipment $655.4K $252.1K
YoY Change 160.01% -86.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $152.6K $135.3K
YoY Change 12.81% -57.83%
Total Long-Term Assets $1.310M $2.048M
YoY Change -36.04% -3.61%
TOTAL ASSETS
Total Short-Term Assets $28.82M $11.82M
Total Long-Term Assets $1.310M $2.048M
Total Assets $30.13M $13.87M
YoY Change 117.26% -36.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.156M $525.7K
YoY Change 119.81% -7.03%
Accrued Expenses $2.858M $2.352M
YoY Change 21.51% 2.12%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K
YoY Change
Total Short-Term Liabilities $4.962M $3.694M
YoY Change 34.32% 14.78%
LONG-TERM LIABILITIES
Long-Term Debt $200.0K $0.00
YoY Change
Other Long-Term Liabilities $72.70K $1.300M
YoY Change -94.41% 18.18%
Total Long-Term Liabilities $72.70K $1.300M
YoY Change -94.41% 18.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.962M $3.694M
Total Long-Term Liabilities $72.70K $1.300M
Total Liabilities $5.745M $5.020M
YoY Change 14.45% 16.99%
SHAREHOLDERS EQUITY
Retained Earnings -$220.4M -$200.5M
YoY Change 9.92% 8.82%
Common Stock $9.585K $7.997K
YoY Change 19.86% 11.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $24.38M $8.848M
YoY Change
Total Liabilities & Shareholders Equity $30.13M $13.87M
YoY Change 117.26% -36.29%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$4.124M -$4.125M
YoY Change -0.03% 10.1%
Depreciation, Depletion And Amortization $110.0K $40.00K
YoY Change 175.0% -82.61%
Cash From Operating Activities -$4.300M -$3.440M
YoY Change 25.0% 5.85%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 22.77M 2.910M
YoY Change 682.47% -80.74%
NET CHANGE
Cash From Operating Activities -4.300M -3.440M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 22.77M 2.910M
Net Change In Cash 18.47M -530.0K
YoY Change -3584.91% -104.48%
FREE CASH FLOW
Cash From Operating Activities -$4.300M -$3.440M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$4.300M -$3.440M
YoY Change 25.0% 5.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001213037
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35558
dei Entity Registrant Name
EntityRegistrantName
CARDIFF ONCOLOGY, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-2004382
dei Entity Address Address Line1
EntityAddressAddressLine1
11055 Flintkote Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
952-7570
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
CRDF
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23227893 shares
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27754813 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10195292 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
109334 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
203480 USD
CY2020Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
954986 USD
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
954957 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
28819133 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
11353729 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
655367 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
877823 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
501894 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
697418 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
152585 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
157576 USD
CY2020Q2 us-gaap Assets
Assets
30128979 USD
CY2019Q4 us-gaap Assets
Assets
13086546 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1155531 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
656304 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2858161 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3260061 USD
CY2020Q2 us-gaap Notes Payable Current
NotesPayableCurrent
70730 USD
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
877607 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
865379 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4962029 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4781744 USD
CY2020Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
46164 USD
CY2019Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
4127 USD
CY2020Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
234270 USD
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
0 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
429776 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
860963 USD
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
72701 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
128368 USD
CY2020Q2 us-gaap Liabilities
Liabilities
5744940 USD
CY2019Q4 us-gaap Liabilities
Liabilities
5775202 USD
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
926 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
60 USD
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21325076 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21325076 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8593633 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8593633 shares
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
9585 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
8312 USD
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
247528273 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
217172528 USD
CY2020Q2 crdf Servicereceivable
Servicereceivable
2765164 USD
CY2019Q4 crdf Servicereceivable
Servicereceivable
971673 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-220389581 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-208897883 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
24384039 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
7311344 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30128979 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13086546 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
42633 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36852 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
110337 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
98873 USD
CY2020Q2 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
0 USD
CY2019Q2 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
1496 USD
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
0 USD
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
1496 USD
CY2020Q2 us-gaap Revenues
Revenues
42633 USD
CY2019Q2 us-gaap Revenues
Revenues
38348 USD
us-gaap Revenues
Revenues
110337 USD
us-gaap Revenues
Revenues
100369 USD
CY2020Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2475722 USD
CY2019Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2830340 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5181413 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5478939 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1669227 USD
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1427967 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3155246 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2803152 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
4144949 USD
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
4258307 USD
us-gaap Operating Expenses
OperatingExpenses
8336659 USD
us-gaap Operating Expenses
OperatingExpenses
8282091 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4102316 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4219959 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-8226322 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-8181722 USD
CY2020Q2 us-gaap Interest Income Operating
InterestIncomeOperating
15671 USD
CY2019Q2 us-gaap Interest Income Operating
InterestIncomeOperating
69761 USD
us-gaap Interest Income Operating
InterestIncomeOperating
51494 USD
us-gaap Interest Income Operating
InterestIncomeOperating
134504 USD
CY2020Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-44144 USD
CY2019Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
23789 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-42037 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
14028 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6257 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1106 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3771 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3116 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4124532 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-4125303 USD
us-gaap Net Income Loss
NetIncomeLoss
-8213094 USD
us-gaap Net Income Loss
NetIncomeLoss
-8030074 USD
CY2020Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6060 USD
CY2019Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6060 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
12120 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
12120 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11491698 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8310463 USD
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7397076 USD
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4131363 USD
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.76
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.94
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.75
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14492159 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5408124 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12201232 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4750993 shares
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
7311344 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
177309 USD
CY2020Q1 crdf Sale Of Stock Value Common And Warrants Net
SaleOfStockValueCommonAndWarrantsNet
-1000001 USD
CY2020Q1 crdf Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1456369 USD
CY2020Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6060 USD
CY2020Q1 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
293017 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4088562 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
6143418 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
281776 USD
CY2020Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
-7500 USD
CY2020Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
17278428 USD
CY2020Q2 crdf Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
4605017 USD
CY2020Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6060 USD
CY2020Q2 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
213492 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4124532 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
24384039 USD
CY2020Q2 crdf Costof Issuanceof Common Stock Preferred Stockand Warrantsfor Clinical Trial Funding Commitment
CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment
616143 USD
CY2020Q2 crdf Warrants Fair Value
WarrantsFairValue
370666 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
10084192 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
200067 USD
CY2019Q1 crdf Costof Issuanceof Common Stock Preferred Stockand Warrantsfor Clinical Trial Funding Commitment
CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment
40000 USD
CY2019Q1 crdf Discountof Issuanceof Common Stock Preferred Stockand Warrantsfor Clinical Trial Funding Commitment
DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment
235640 USD
CY2019Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
-40000 USD
CY2019Q1 crdf Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
3282266 USD
CY2019Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6060 USD
CY2019Q1 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
70487 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-3904771 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
9686181 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
148834 USD
CY2019Q2 crdf Sale Of Stock Value Common And Warrants Net
SaleOfStockValueCommonAndWarrantsNet
-2902740 USD
crdf Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1564 USD
CY2019Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6060 USD
CY2019Q2 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
240279 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-4125303 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
8848235 USD
us-gaap Net Income Loss
NetIncomeLoss
-8213094 USD
us-gaap Net Income Loss
NetIncomeLoss
-8030074 USD
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
34169 USD
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
233909 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
248958 USD
us-gaap Share Based Compensation
ShareBasedCompensation
459085 USD
us-gaap Share Based Compensation
ShareBasedCompensation
348901 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-42037 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
14028 USD
crdf Releaseofclinicaltrialfundingcommitmentforservicesreceived
Releaseofclinicaltrialfundingcommitmentforservicesreceived
506509 USD
crdf Releaseofclinicaltrialfundingcommitmentforservicesreceived
Releaseofclinicaltrialfundingcommitmentforservicesreceived
310766 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-4991 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
32464 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-94146 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-45474 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
29 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-163950 USD
crdf Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-161355 USD
crdf Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-147974 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-514239 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
387046 USD
crdf Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-418959 USD
crdf Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-379662 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-55667 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
0 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7665787 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6803159 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5274 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5274 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
92648 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
97260 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18801924 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2902740 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-7500 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-40000 USD
crdf Class Of Warrant Or Right Exercise Costs
ClassOfWarrantOrRightExerciseCosts
393285 USD
crdf Class Of Warrant Or Right Exercise Costs
ClassOfWarrantOrRightExerciseCosts
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6125884 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3283830 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
305000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25225308 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6146570 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
17559521 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-661863 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10195292 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11453133 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27754813 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10791270 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
800 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
800 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
11453 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
crdf Stock Issuance Costs Incurred But Not Yet Paid
StockIssuanceCostsIncurredButNotYetPaid
523495 USD
crdf Stock Issuance Costs Incurred But Not Yet Paid
StockIssuanceCostsIncurredButNotYetPaid
0 USD
crdf Warrant Exercise Costs Incurred But Not Yet Paid
WarrantExerciseCostsIncurredButNotYetPaid
64498 USD
crdf Warrant Exercise Costs Incurred But Not Yet Paid
WarrantExerciseCostsIncurredButNotYetPaid
0 USD
crdf Preferred Stock Dividend Accrued
PreferredStockDividendAccrued
12120 USD
crdf Preferred Stock Dividend Accrued
PreferredStockDividendAccrued
12120 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27800000 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7397076 USD
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4131363 USD
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3493570 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11491698 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8310463 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-7397076 USD
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4131363 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11491698 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8310463 USD
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14492159 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5408124 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12201232 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4750993 shares
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.76
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.94
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.75
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17805051 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5452523 shares
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
655367 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3482116 USD
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2838203 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2604293 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
877823 USD
crdf Lessee Operating Lease Monthly Rent Payment
LesseeOperatingLeaseMonthlyRentPayment
78000 USD
crdf Lessee Operating Lease Annual Rent Increase Percentage
LesseeOperatingLeaseAnnualRentIncreasePercentage
0.03
crdf Lessee Operating Lease Number Of Renewal Options
LesseeOperatingLeaseNumberOfRenewalOptions
1 renewal_option
CY2020Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
crdf Lessee Operating Lease Annual Rent Increase Percentage
LesseeOperatingLeaseAnnualRentIncreasePercentage
0.03
crdf Lessor Number Of Subleases
LessorNumberOfSubleases
2 lease
CY2020Q2 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
34169 USD
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
139283 USD
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
112115 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
246028 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
225708 USD
CY2020Q2 us-gaap Sublease Income
SubleaseIncome
72793 USD
CY2019Q2 us-gaap Sublease Income
SubleaseIncome
99937 USD
us-gaap Sublease Income
SubleaseIncome
145587 USD
us-gaap Sublease Income
SubleaseIncome
199874 USD
CY2020Q2 us-gaap Lease Cost
LeaseCost
66490 USD
CY2019Q2 us-gaap Lease Cost
LeaseCost
12178 USD
us-gaap Lease Cost
LeaseCost
100441 USD
us-gaap Lease Cost
LeaseCost
25834 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
501894 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
697418 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
877607 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
865379 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
429776 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
860963 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1307383 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1726342 USD
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.065
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.065
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
236385 USD
CY2019Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
229574 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
469463 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
455938 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
395916 USD
CY2020Q2 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
145587 USD
CY2020Q2 crdf Lessee Operating Lease Liability Payments Net Of Sublease Income Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear
250329 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
968165 USD
CY2020Q2 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
291173 USD
CY2020Q2 crdf Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year One
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne
676992 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5868 USD
CY2020Q2 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
0 USD
CY2020Q2 crdf Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Two
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo
5868 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3423 USD
CY2020Q2 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
0 USD
CY2020Q2 crdf Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Three
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree
3423 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1373372 USD
CY2020Q2 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
436760 USD
CY2020Q2 crdf Lessee Operating Lease Liability Payments Net Of Sublease Income Due
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue
936612 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
65989 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1307383 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
281776 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
148834 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
459085 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
348901 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
764724 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
279760 USD
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10589482 shares
CY2019Q4 crdf Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
4.08
CY2020Q1 crdf Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights
ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
P3Y8M12D
crdf Class Of Warrant Or Right Number Granted
ClassOfWarrantOrRightNumberGranted
5831451 shares
crdf Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted
1.70
crdf Class Of Warrant Or Right Number Exercised
ClassOfWarrantOrRightNumberExercised
4091498 shares
crdf Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised
1.59
CY2020Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12329435 shares
CY2020Q2 crdf Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
3.78
crdf Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights
ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
P4Y6M
CY2019Q2 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
333333 shares
CY2019Q1 crdf Servicereceivable
Servicereceivable
1675000 USD
CY2020Q2 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1546700 shares
CY2020Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2213115 shares
CY2020Q2 crdf Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock
DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
2700000 USD
CY2020Q2 crdf Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
184426 shares
CY2020Q2 crdf Class Of Warrant Or Right Months Until Exercisable
ClassOfWarrantOrRightMonthsUntilExercisable
P6M
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.05
CY2020Q2 crdf Class Of Warrant Or Right Expiration Term
ClassOfWarrantOrRightExpirationTerm
P5Y6M
CY2020Q2 crdf Warrants Fair Value
WarrantsFairValue
370666 USD
CY2020Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
800000 shares
CY2020Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
1000000.0 USD
CY2020Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
904970 shares
CY2020Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
1100000 USD
CY2020Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
810000 USD
CY2020Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
447761 shares
CY2020Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.34
CY2020Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
146854 shares
CY2020Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.43
CY2020Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1205400 shares
CY2020Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
2500000 USD

Files In Submission

Name View Source Status
0001628280-20-012428-index-headers.html Edgar Link pending
0001628280-20-012428-index.html Edgar Link pending
0001628280-20-012428.txt Edgar Link pending
0001628280-20-012428-xbrl.zip Edgar Link pending
crdf-063020exhibit311.htm Edgar Link pending
crdf-063020exhibit312.htm Edgar Link pending
crdf-063020exhibit321.htm Edgar Link pending
crdf-063020exhibit322.htm Edgar Link pending
crdf-20200630.htm Edgar Link pending
crdf-20200630.xsd Edgar Link pending
crdf-20200630_cal.xml Edgar Link unprocessable
crdf-20200630_def.xml Edgar Link unprocessable
crdf-20200630_htm.xml Edgar Link completed
crdf-20200630_lab.xml Edgar Link unprocessable
crdf-20200630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending